LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

Whether the LSC17 gene expression can improve risk stratification in the context of next generation sequencing–based risk stratification and measurable residual disease (MRD) in patients with intensively treated AML has not been explored. We analyzed LSC17 in 504 adult patients prospectively treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasseur, Loïc, Fenwarth, Laurène, Lambert, Jérôme, de Botton, Stéphane, Figeac, Martin, Villenet, Céline, Heiblig, Maël, Dumas, Pierre-Yves, Récher, Christian, Berthon, Céline, Lemasle, Emilie, Lebon, Delphine, Lambert, Juliette, Terré, Christine, Celli-Lebras, Karine, Dombret, Hervé, Preudhomme, Claude, Cheok, Meyling, Itzykson, Raphael, Duployez, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410128/
https://www.ncbi.nlm.nih.gov/pubmed/37205853
http://dx.doi.org/10.1182/bloodadvances.2023010155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410128/
https://www.ncbi.nlm.nih.gov/pubmed/37205853
http://dx.doi.org/10.1182/bloodadvances.2023010155

Ejemplares similares